The Efficacy, Safety of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 ASCO Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.
During the discussion, Strosberg details the findings of the phase 3 trial in regard to the efficacy and safety of lutetium Lu 177 dotatate for patients with advanced midgut neuroendocrine tumors.
